Wolfe Research identifies 12 companies with highest activist attractiveness scores

Wolfe Research identifies a set of firms ranking in the 99th percentile on its Activist Attractiveness Score — examples include Globant, Molina Healthcare (MOH), Humana (HUM), QUALCOMM (QCOM), Enphase Energy (ENPH) and others. Wolfe flags that companies at or above the 75th percentile are more vulnerable to shareholder engagement and also lists names with the largest recent score jumps (e.g., HNI, ServiceNow (NOW), Armstrong World (AWI), Avista (AVA), BJ’s (BJ), PSEG (PEG), Ionis (IONS), SkyWest (SKYW)). Monitor these specific stocks for potential activist campaigns that can move individual equities (historically often in the ~1–3% range); the item is unlikely to have broad market impact.

Analysis

Activist engagement in the current market is a catalyst that compresses time-to-value: when dissidents can credibly demand board changes or asset sales, expect realization windows of 3–18 months rather than multi-year turnarounds. That accelerates liquidity events—share buybacks, carve-outs, or sale processes—that typically rerate cash-rich but operationally stagnant businesses by 15–40% if implemented cleanly, but can instead amplify volatility by 20–40% on failed campaigns or regulatory pushback.

Second-order winners include advisors (IBs, proxy firms) and buyers of non-core assets who can acquire businesses at a small control premium; losers are firms in the same supply chains that lose scale benefits when peers are broken up, and suppliers whose payment terms get tightened during restructuring. For tech licensors and integrated manufacturers, separation or asset-light refocusing can unlock a valuation gap of ~5–10 turns of EBITDA, but those moves materially increase legal, regulatory and execution risk—especially where cross-border IP or export controls exist.

Key risk vectors and catalysts to watch are 13D filings, proxy timelines (3–9 months to board votes), and liquidity tightening which raises the probability that activists extract asset sales rather than long-term operational fixes. Reversal scenarios include clear organic outperformance, credible management-led strategic reviews that remove the activist rationale, or macro illiquidity that forces activists to step back; each can flip expected returns within a single quarter.

Key Decisions for Investors

• Buy QCOM 12–18 month call spread (bullish diagonal or calendar if available): size 2–4% notional. Rationale: asymmetric upside if governance push forces separation / capital returns; target +30% potential return vs max loss = option premium (100%). Place stop if underlying falls 15% on activist failure news.
• Relative-value pair: Long QCOM / Short GLOB, 6–12 months, equal-dollar exposure. Rationale: favor cash-rich, high-ROIC franchise over lower-governance small-cap; expect 15–25% relative outperformance. Risk control: cut pair if spread moves against by 10% or within 30 days of an announced settlement.
• Buy 3–6 month puts on governance-poor small caps (e.g., GENI), concentrated tactical hedge 1–2% portfolio. Rationale: activist rejection or execution miss often triggers 20–40% downside in these names; limited-cost way to hedge activism-driven volatility. Exit on catalyst resolution or volatility compressing by half.
• Event-driven long in select healthcare targets (e.g., MOH), 9–12 months, funded by small option sales against cyclicals. Rationale: activist-driven M&A or margin fixes can deliver 10–20% upside; downside limited by regulatory/sector risk—manage with 12% hard stop and scale into confirmed strategic-review announcements.